News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Protalex, Inc. (PRTX) Initiates Enrollment of Final Cohort in Phase 1b Trial of PRTX-100 in Active Rheumatoid Arthritis Patients


10/31/2013 12:16:59 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SUMMIT, N.J.--(BUSINESS WIRE)--Protalex, Inc. (OTCQB:PRTX), a clinical-stage biopharmaceutical company, today announced that following completion of Cohort 4 which expanded the 3.0 mcg, 6.0 mcg, and 12.0 mcg/kg dose cohorts by an additional 9 patients, the Company has initiated enrollment of its fifth and final cohort (Cohort 5) in its multicenter Phase 1b randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (RA). PRTX-100 is an investigational drug incorporating a highly purified form of Staphylococcal Protein A.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES